直覺手術 (ISRG) 2002 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello and welcome to the Intuitive Surgical, Inc. fourth quarter 2002 and year-end earnings release conference call. At the request of Intuitive Surgical the call is recorded for instant replay purposes. At this time I would like to turn over to Ben Gong, Vice President of Finance, Treasurer and Corporate Controller for Intuitive Surgical. Sir, you may begin

    各位好,歡迎參加 Intuitive Surgical, Inc. 2002 年第四季及全年財報新聞稿電話會議。應 Intuitive Surgical 要求,本次電話會議將錄音以供即時重播之用。此刻我想把時間交給 Intuitive Surgical 財務副總裁、財務長兼公司主計長 Ben Gong。先生,您可以開始了

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • Thank you and welcome to the conference call. With me today we have Lonnie Smith, our President and CEO; Susan Barnes, our Chief Financial Officer; Aleks Cukic, our Vice President of Business Development and Strategic Planning; David Shaw, our Vice President of Legal Affairs, and Corporate Counsel; and Fred Moll, our Co-Founder and Medical Director.

    謝謝,歡迎各位參加本次電話會議。今天與我一同出席的有:我們的總裁暨執行長 Lonnie Smith;我們的財務長 Susan Barnes;我們的業務發展與策略規劃副總裁 Aleks Cukic;我們的法務副總裁兼公司法律顧問 David Shaw;以及共同創辦人兼醫療總監 Fred Moll。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward looking statements. Actual results may differ materially from those express or implied as a result of certain risks and uncertainties. They are described in detail in the company's Securities and Exchange Commissions filings. Prospective investors are cautioned not to place undue reliance on such forward looking statements.

    在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示者有重大差異。相關內容已在公司向美國證券交易委員會(SEC)提交的文件中詳加說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note this conference call will be available for audioreplay on our website at www.intuitivesurgical.com on the audioarchives section under our Investor Relations page. In addition today's press release has been posted to our website. Today's format will consist of providing you with highlights of the fourth quarter as described in the press release announced earlier today followed by a question and answer session.

    請注意,本次電話會議將可於我們網站 www.intuitivesurgical.com 的 Investor Relations(投資人關係)頁面下之 audioarchives(音訊存檔)區提供錄音重播。此外,今天的新聞稿也已張貼於我們網站。今天的流程將先提供第四季重點摘要(如今日稍早發布之新聞稿所述),接著進行問答。

  • First, Lonnie will present the business highlights of the fourth quarter. Susan will follow with a review of our fourth quarter and full year financial results and provide an outlook for the next year. Next Aleks will discuss sales and marketing and finally David will update you on intellectual property issues. Following that we will host a question and answer session.

    首先,Lonnie 將說明第四季的業務重點。接著 Susan 將回顧我們第四季與全年財務結果,並提供對明年的展望。然後 Aleks 將討論銷售與行銷,最後 David 將向各位更新智慧財產權相關議題。之後我們將進行問答時間。

  • With that I would like to introduce Lonnie Smith, our President and CEO.

    接下來我想介紹我們的總裁暨執行長 Lonnie Smith。

  • - President and CEO

    - President and CEO

  • Thank you, Ben. I would like to thank each of you for taking the time to join us for today's conference call.

    謝謝你,Ben。感謝各位撥冗參加今天的電話會議。

  • I will begin with highlights of the fourth quarter. As we announced last month, we achieved record quarterly revenues, systems shipped and recurring revenue. During the fourth quarter we achieved total revenue of $21.1 million, up 32% from prior year. Grew recurring revenue to $4.7 million, up 105% from prior year and shipped 17 da Vinci surgical systems, ending the year with 149 systems installed worldwide.

    我先從第四季重點開始。如同我們上個月宣布的,我們創下單季營收、出貨系統數以及經常性收入的新高紀錄。第四季總營收達 2,110 萬美元,較去年同期成長 32%。經常性收入成長至 470 萬美元,較去年同期成長 105%,並出貨 17 套達文西(da Vinci)手術系統,使全年全球安裝量達 149 套。

  • We continue to make progress in our financial metrics in the fourth quarter. Our gross profit margin reached a new high of 55%. Our fourth quarter operating expenses were $14.6 million, down $1 million from our last quarter's results. Our fourth quarter net loss was $2.6 million or seven cents a share. This is an indication of progress toward our goal of achieving profitability by the end of this year.

    我們在第四季的財務指標持續取得進展。毛利率達到 55% 的新高。第四季營業費用為 1,460 萬美元,較上一季減少 100 萬美元。第四季淨損為 260 萬美元,或每股 0.07 美元。這顯示我們正朝著在今年年底前達成獲利的目標邁進。

  • Finally, we had a cash positive quarter. Ending the year with $50.8 million, up $2.3 million from the end of the third quarter.

    最後,我們本季現金流為正。年底現金為 5,080 萬美元,較第三季末增加 230 萬美元。

  • Now, turning to operations, we have made significant progress in the cardiac segment. In November of last year, the FDA cleared da Vinci surgical system to perform minimally invasive mitral valve repair. This intercardiac clearance for the da Vinci system represents the first cardiac clearance by the FDA for any operative robotic system. Randy Chipwood, [ph] Chairman of the Department of Surgery at Brody [ph] School of Medicine at East Carolina University and principal investigator in our multi [INAUDIBLE] trial commented for the first time we will be able to offer a wider range of patients a minimally invasive intercardiac procedure to repair the mitral valve. He said this news from the FDA will allow more patients to enjoy the benefits of high precision minimally invasive surgery robotic surgery. These benefits include less pain and trauma, shorter hospital stays, quick recovery, and a better cosmetic result.

    接著談營運面,我們在心臟領域取得重大進展。去年 11 月,FDA 核准達文西手術系統可用於微創二尖瓣修補手術。達文西系統取得此項心臟適應症核准,代表 FDA 首次對任何手術機器人系統核准心臟手術適應症。東卡羅來納大學 Brody [ph] 醫學院外科系主任暨我們多中心 [INAUDIBLE] 試驗的主要研究者 Randy Chipwood [ph] 表示,這是首次能為更廣泛的病患提供微創心臟內手術以修補二尖瓣。他說,這項 FDA 的消息將讓更多病患享有高精準度的微創機器人手術之益處。這些益處包括疼痛與創傷更少、住院時間更短、恢復更快,以及更佳的外觀效果。

  • Last week we announced we had added a second cardiac procedure to our intercardiac clearance for totally endoscopic atrial septal defect closure or ASD. Hospitals can now use the da Vinci surgical system to minimally invasively close a hole between the chambers of the the patient's heart. Michael Argenziano, Assistant Professor of Surgery at Columbia University, and Director of Minimally Invasive and Robotic Cardiac Surgery at New York Presbyterian Hospital performed 19 robotic ASD closures. The results were recently presented at the scientific session of the American Heart Association meeting in November. Dr. Argenziano reported that the da Vinci surgical system can be utilized to perform open heart procedures safely and effectively.

    上週我們宣布,在心臟適應症核准範圍內新增第二項心臟手術:全內視鏡心房中隔缺損封閉術(ASD)。醫院現在可使用達文西手術系統,以微創方式封閉病患心臟腔室之間的孔洞。哥倫比亞大學外科助理教授、紐約長老會醫院微創與機器人心臟外科主任 Michael Argenziano 已完成 19 例機器人 ASD 封閉術。相關結果近期已於 11 月美國心臟協會年會的科學會議中發表。Argenziano 醫師報告指出,達文西手術系統可安全且有效地用於開心手術。

  • The closed chest approach furthermore, his outcome suggests the patients undergoing ASD closure with the da Vinci have a superior post operative quality of life than those undergoing other surgical approaches. Thus, this technique represents an option for patients seeking a reliable ASD closure without [INAUDIBLE] or orthotocotomy [ph] and uncertainty of transcatheter techniques.

    此外,採用閉胸方式時,他的結果顯示,使用達文西進行 ASD 封閉術的病患,其術後生活品質優於採用其他手術方式者。因此,對於希望獲得可靠 ASD 封閉、且不需 [INAUDIBLE] 或正中開胸(orthotocotomy [ph]),並避免經導管技術不確定性的病患而言,這項技術提供了一個選擇。

  • These clearances bring many of the promises of the da Vinci to actual practice in the United States. We can now specifically market the da Vinci system for these two cardiac procedures. These are the type of procedures that maximize the value the da Vinci surgical system delivers to patients, surgeons and hospitals. In cases like mitral valve repair and ASD closure where the da Vinci enables an endoscopic approach, the system delivers incremental revenues to the hospitals and surgeons through incremental patients. It reduces the cost by reducing the length of stay and complication rates.

    這些核准使達文西在美國的多項承諾得以真正落實於臨床實務。我們現在可以針對這兩項心臟手術明確行銷達文西系統。這類手術最能彰顯達文西手術系統為病患、外科醫師與醫院所帶來的價值。在二尖瓣修補與 ASD 封閉等案例中,達文西可實現內視鏡手術途徑,並透過新增病患量為醫院與醫師帶來增量營收。同時也能藉由縮短住院天數與降低併發症發生率來降低成本。

  • Very importantly, the shorter length of hospital stay exhilarates patient through put and thereby adds valuable capacity to the hospital without an increase in the staffing cost associated with additional hospital beds. This combination of increased revenue, reduced operating cost, increased capacity, and incremental profit contribution provide a very attractive value proposition to the hospitals. The value added to the patient is obvious. Shorter hospital stay, less post operative pain, less risk of infection, less blood loss and associated transfusions, less scarring and approved kosnethis [ph], fast recovery and return to normal daily activities.

    更重要的是,較短的住院天數可提升病患周轉率,因而在不增加與新增病床相關的人力成本下,為醫院增加寶貴的收治量能。營收增加、營運成本降低、容量提升與增量獲利貢獻的組合,為醫院提供了非常具吸引力的價值主張。對病患而言,附加價值顯而易見。住院時間更短、術後疼痛更少、感染風險更低、失血量及相關輸血更少、疤痕更少且外觀更佳(approved kosnethis [ph])、恢復更快並能回到正常日常活動。

  • These cardiac clearances are another example of the company's consistent track record, discipline and commitment to execution of key business objectives within our plan time horizons. On that note, we logged a significant number of cases during the fourth quarter in our ongoing stopped heart coronary bypass trial. Results are positive and we continue to expect FDA clearance by the end of this year.

    這些心臟適應症核准,再次展現公司一貫的良好執行紀錄、紀律,以及在既定時程內落實關鍵業務目標的承諾。同時,我們在第四季於進行中的停跳心冠狀動脈繞道試驗中累積了相當多的案例。結果正面,我們仍預期在今年年底前取得 FDA 核准。

  • One final cardiac milestone -- the first beating heart T cap [ph], totally endoscopic coronary bypass, performed in the U.S. was successfully completed by Dr. Sudhir Srivastava at Odessa Regional Medical Center this past Monday under a physician-sponsored FDA investigational device exemption. The procedure was completed in less than four hours and the patient was released from the hospital 24 hours post op and is doing great.

    最後一項心臟里程碑——美國首例跳動心 T cap [ph] 全內視鏡冠狀動脈繞道手術,已於本週一在醫師主導的 FDA 研究用醫療器材豁免(IDE)下,由 Sudhir Srivastava 醫師於 Odessa Regional Medical Center 成功完成。該手術在不到四小時內完成,病患於術後 24 小時即出院,目前狀況良好。

  • Before I turn the time to Susan, I would like to share one last observation. When we started the company, one of the objectives was to create a surgical system that would help "good surgeons become great surgeons." I think that's a term that Fred wrote. That was a pretty ambitious goal at the time. However, data now being published and reported at recent surgical meetings confirms we have made significant progress toward that goal.

    在我把時間交給 Susan 之前,我想分享最後一點觀察。當我們創立公司時,其中一個目標是打造一套外科手術系統,能幫助「好的外科醫師成為偉大的外科醫師」。我想那是 Fred 寫的用語。在當時那是一個相當雄心勃勃的目標。然而,近期外科會議上發表與報告的資料證實,我們已朝該目標取得顯著進展。

  • Doctor Mani Menon, Chief of Urology at the Henry Ford Hospital and the Vattikuti Institute recently presented data that compares results of his last 100 open prostatectomies with the first 200 da Vinci prostatectomies. He used six primary outcome metrics for the comparison. The first, removal of the cancer. Measured by net margins. His open procedures were 76%. His procedures with da Vinci or closed procedure were 94%, a significant improvement. In terms of continence after six months, measured by no pads, no diapers, his results were 60% and 96% with da Vinci. In terms of potency, measured by ability to have sexual intercourse after six months, his results were 33% open and 66% with da Vinci. In terms of safety measured by no complications. 85% open and 98% with da Vinci. Pain, measured on a 1-10 score, seven open and three with da Vinci. Finally blood loss measured by the need for transfusion, he had 11% transfusion rate open and 0 with da Vinci.

    亨利福特醫院(Henry Ford Hospital)泌尿科主任暨 Vattikuti 研究所的 Mani Menon 醫師,最近發表了比較其最後 100 例開放式前列腺切除術與前 200 例達文西(da Vinci)前列腺切除術結果的數據。他使用六項主要結果指標進行比較。第一項是癌症切除。以切緣陰性率衡量。他的開放式手術為 76%。使用達文西的手術(或閉合式手術)為 94%,有顯著改善。就六個月後的控尿能力而言,以不需護墊、不需尿布衡量,他的結果為開放式 60%,達文西 96%。就性功能而言,以六個月後能進行性行為的能力衡量,他的結果為開放式 33%,達文西 66%。就安全性而言,以無併發症衡量:開放式 85%,達文西 98%。疼痛以 1–10 分量表衡量,開放式為 7 分,達文西為 3 分。最後,失血量以是否需要輸血衡量,開放式輸血率為 11%,達文西為 0%。

  • Dr. Menon also compared his first 200 da Vinci prostatectomies with best in class in each category from published data. In other words, he compared his minimally invasive results using the da Vinci system with the open results of a dream team of the best urologists in the world. Dr. Menon's results results with the da Vinci surgical system were significantly better than the best published result in nearly every category including continence, potency, safety, pain, and blood loss.

    Menon 醫師也將其前 200 例達文西前列腺切除術,與已發表資料中各類別的同業最佳(best in class)進行比較。換言之,他把使用達文西系統的微創手術結果,與由全球最頂尖泌尿科醫師「夢幻團隊」所做的開放式手術結果相比。Menon 醫師使用達文西手術系統的結果,在幾乎每一個類別都顯著優於已發表的最佳結果,包括控尿、性功能、安全性、疼痛與失血量。

  • The bottom line with da Vinci for Dr. Menon and the Henry Ford hospital system is: one, better outcomes for the patient; two, dramatic growth in the number of prostatectomy patients. I think he was doing about 170 before and did something near 400 -- 300 this year. And anticipates 400 plus next year. And three, significant reduction in the length of hospital stay.

    對 Menon 醫師與亨利福特醫院體系而言,達文西的核心結論是:第一,病患有更好的治療結果;第二,前列腺切除術病患數量大幅成長。我想他之前大約做 170 例,今年做了接近 400——大概 300 例。並預期明年 400 例以上。第三,住院天數顯著縮短。

  • With that, I will pass the time over to Susan who will discuss our fourth quarter financial results.

    接下來,我把時間交給 Susan,由她說明我們第四季的財務結果。

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • Thank you, Lonnie. As Lonnie mentioned earlier, we had many financial milestones this quarter. We realized directed revenue of $21.1 million, up 32% from our fourth quarter 2001. Gross margin improved to 55%. We grew recurring revenue to $4.7 million, up 105% over last year. Our operating loss decreased to $2.6 million or seven cents a share, representing our smallest quarterly loss since we started selling da VInci surgical systems in 1999. We were $2.3 million cash positive during the fourth quarter ending the year with $50.8 million in cash.

    謝謝你,Lonnie。如 Lonnie 先前提到的,本季我們達成了許多財務里程碑。我們實現直接營收 2,110 萬美元,較 2001 年第四季成長 32%。毛利率提升至 55%。經常性營收成長至 470 萬美元,較去年成長 105%。營業虧損降至 260 萬美元(每股 0.07 美元),為自 1999 年開始銷售達文西手術系統以來最小的單季虧損。第四季我們現金流為正 230 萬美元,年底現金餘額為 5,080 萬美元。

  • Now going into the details, our fourth quarter 2002 revenue was $21.1 million dollars, up 32% from the fourth quarter of 2001 revenue of $16 million. We shipped 17 da Vinci surgical systems during the quarter. With 17 total units shipped, we are up 2 compared to 15 units shipped during the fourth quarter of 2001. We now have cumulative placements of 149 systems. 100 in the United States, 40 in Europe and 9 in the rest of the world.

    接著說明細節,2002 年第四季營收為 2,110 萬美元,較 2001 年第四季的 1,600 萬美元成長 32%。本季我們出貨 17 套達文西手術系統。以 17 套總出貨量計,較 2001 年第四季出貨 15 套增加 2 套。目前累計裝機(placements)達 149 套:美國 100 套、歐洲 40 套、世界其他地區 9 套。

  • Our January press release and subsequent conference call, we estimated approximately $20 million in fourth quarter revenue. Our auditors have since completed the review and we are now able to disclose revenue actually exceeded that estimate by $1.1 million. Included in the $21.1 million is the recognition of $400,000 of revenue related to obtaining FDA mitral valve clearance.

    在我們 1 月的新聞稿及後續電話會議中,我們估計第四季營收約 2,000 萬美元。審計師其後已完成審閱,我們現在可以揭露實際營收較該估計高出 110 萬美元。2,110 萬美元中包含與取得 FDA 二尖瓣核准(clearance)相關的 40 萬美元營收認列。

  • Total Q4 2002 revenue by product group was as follows: System $16.4 million. Instruments and accessories, $3.2. And service, $1.5. Recurring revenue grew to $4.7 million during the fourth quarter, up 105% from the $2.3 million last year. Recurring revenue grew to 22% of total revenue this fourth quarter, as compared to 14% in the fourth quarter last year. Our recurring revenue continues to climb each quarter as we place more systems and our surgeons perform more robotic procedures.

    2002 年第四季依產品群組的總營收如下:系統 1,640 萬美元。器械與配件 320 萬美元。服務 150 萬美元。第四季經常性營收成長至 470 萬美元,較去年 230 萬美元成長 105%。本季經常性營收占總營收 22%,相較去年第四季為 14%。隨著我們部署更多系統、外科醫師執行更多機器人手術,我們的經常性營收每季持續攀升。

  • For the fiscal year ended December 31, 2001 -- 2002, we have total sales of $72 million, up $2.3 million or 39% compared to 2001. We shipped 60 da Vinci surgical systems in 2002 compared to 49 in 2001. Total recurring revenue was $15.1 million, up $8.1 million or 116% over the 2001 recurring revenue of $7 million. Gross margin for the fourth quarter of 2002 was 55% compared with 42.3% for the fourth quarter of 2001. Our fourth quarter 2002 gross margin improvement was driven by higher ASP's on our system sales and improved manufacturing processes. Further, we have been incurring significantly lower warranty costs and we made a one-time adjustment this quarter to decrease our warranty reserves.

    截至 12 月 31 日止的會計年度(2001—2002),我們總銷售額為 7,200 萬美元,較 2001 年增加 230 萬美元或 39%。2002 年我們出貨 60 套達文西手術系統,2001 年為 49 套。經常性營收總額為 1,510 萬美元,較 2001 年的 700 萬美元增加 810 萬美元或 116%。2002 年第四季毛利率為 55%,相較 2001 年第四季為 42.3%。2002 年第四季毛利率改善主要來自系統銷售較高的平均售價(ASP)以及製造流程改善。此外,我們承擔的保固成本顯著降低,並於本季進行一次性調整以降低保固準備金。

  • In order to compare quarter over quarter annually, we need to remind you that the fourth quarter of 2001 gross margin was negatively impacted by the final $1 million IBM royalty charge taken to cost of sales. Excluding the impact of this item, fourth quarter 2001 gross margin would have been 48.5% versus the 55 for Q4, 2002. Full year 2002 gross margin improved to 52% from last year's 45.4.

    為了進行年度的逐季比較,我們需要提醒各位:2001 年第四季毛利率受到最後 100 萬美元 IBM 權利金費用列入銷貨成本的負面影響。若排除該項目的影響,2001 年第四季毛利率將為 48.5%,相較 2002 年第四季的 55%。2002 年全年毛利率提升至 52%,高於去年的 45.4%。

  • Total operating expenses for the fourth quarter of 2002 were $14.6 million, up $2.8 million or 24% compared to fourth quarter of 2001. Operating expenses were one million less than recorded during the third quarter of this year.

    2002 年第四季營業費用總額為 1,460 萬美元,較 2001 年第四季增加 280 萬美元或 24%。營業費用較今年第三季所記錄的金額少 100 萬美元。

  • SG&A were $10.6 million in the fourth quarter of 2002, up approximately $2.6 million from the $8 million in the fourth quarter of 2001. The increase over prior year was driven by growth in our field sales and customer support organization as well as legal fees. Full year 2002 SG&A expenses were $57.7 million, up 32% $from 43.8 million in 2001.

    2002 年第四季銷售、一般及行政費用(SG&A)為 1,060 萬美元,較 2001 年第四季的 800 萬美元增加約 260 萬美元。較前一年度增加主要來自我們外勤銷售與客戶支援組織的擴張,以及法律費用。2002 年全年 SG&A 費用為 5,770 萬美元,較 2001 年的 4,380 萬美元增加 32%。

  • Research and development expense was $4 million for the fourth quarter of 2002, up approximately $200,000 from $3.8 million in the fourth quarter of last year. The increase versus prior year resulted primarily from increased clinical trial activity in Q4 2002. Full year 2002 R&D expenses totalled $16.8 million, up 21% from $13.9 million in 2001.

    2002 年第四季研發費用為 400 萬美元,較去年第四季的 380 萬美元增加約 20 萬美元。與前一年相比的增加主要來自 2002 年第四季臨床試驗活動增加。2002 年全年研發費用合計 1,680 萬美元,較 2001 年的 1,390 萬美元增加 21%。

  • We ended the quarter with 291 regular employees, up 13 from the previous quarter end. 11 of the 13 additions were made to booster the U.S. field sales and support team in preparation for 2003. We believe we have a critical mass of field sales and support personnel and intend to grow the organization at a much slower rate in 2003.

    本季末我們共有 291 名正式員工,較上一季季末增加 13 人。新增的 13 人中有 11 人是為了在 2003 年前強化美國現場銷售與支援團隊而增聘。我們認為現場銷售與支援人員已達到關鍵規模,並計畫在 2003 年以更慢的速度擴編組織。

  • Noncash deferred compensation and patent amortization expenses represented $300,000 of total operating expenses in Q4 2002, compared to $500,000 in Q4, 2001. The balance of deferred compensation is now down to $200,000 and should be completely amortized early next year. Our balance of unamortized patents is now $2.6 million which will be taken into the income statements at a straight line rate of $197,000 per quarter until it's fully expense.

    2002 年第四季,非現金遞延薪酬與專利攤銷費用占總營運費用 30 萬美元,相較於 2001 年第四季的 50 萬美元。遞延薪酬餘額目前已降至 20 萬美元,預計將於明年初完全攤銷完畢。未攤銷專利餘額目前為 260 萬美元,將以每季 19.7 萬美元的直線法列入損益表,直到完全費用化為止。

  • Other income expense approximately $400,000 from Q4, 2002 compared to $800,000 in 2001. The decrease is mainly due to lower cash balances and lower rates of return earned on cash investments. Our net loss for the fourth quarter 2002 was $2.6 million or seven cents per share compared to $4.3 million or 12 cents per share in the fourth quarter of 2001. Our narrowing net loss reflects progress in achieving profitability. We intend to be profitable by the fourth quarter of 2003. Basic and diluted shares outstanding for EPS calculations were $36.6 million shares for the fourth quarter of 2002 compared to $36.1 for the same period last year.

    其他收入(費用)約為 40 萬美元(2002 年第四季),相較於 2001 年的 80 萬美元。下降主要由於現金餘額較低,以及現金投資所獲得的報酬率較低。2002 年第四季淨損為 260 萬美元(每股 0.07 美元),相較於 2001 年第四季淨損 430 萬美元(每股 0.12 美元)。淨損縮小反映我們在達成獲利方面的進展。我們計畫在 2003 年第四季達成獲利。用於每股盈餘(EPS)計算的基本及稀釋後流通在外股數,2002 年第四季為 3,660 萬股,去年同期為 3,610 萬股。

  • Now going on to our balance sheet. We ended the quarter with $50.8 million in cash, up $2.3 million from previous quarter end. Our positive cash quarter was driven primarily by working capital provided from accounts receivable and inventory reduction offset by the net loss. Note that our Q4 net loss of $2.6 included $1.2 million of noncash expenses, comprised of patent amortization and deferred compensation I described before as well as depreciation.

    接著說明資產負債表。本季末現金為 5,080 萬美元,較上一季季末增加 230 萬美元。本季現金增加主要來自應收帳款回收與存貨降低所提供的營運資金,並抵銷了淨損的影響。請注意,我們第四季 260 萬美元的淨損中包含 120 萬美元的非現金費用,包含前述的專利攤銷與遞延薪酬,以及折舊。

  • We ended the quarter with an accounts receivable balance of $16.9 million, down $2.2 million from the quarter end. The decrease was due to successful collection efforts during the fourth quarter. Our average days sales outstanding was 72 days down from 100 at the end of Q3. Ending net inventory for the quarter was $8.7 million, down about $1.1 million from the previous quarter end. Our annual inventory turns are now about 4.4 compared to 3.4 ending the third quarter.

    本季末應收帳款餘額為 1,690 萬美元,較季末減少 220 萬美元。下降係因第四季收款作業成效良好。平均應收帳款週轉天數為 72 天,較第三季末的 100 天下降。本季末淨存貨為 870 萬美元,較上一季季末減少約 110 萬美元。年化存貨週轉率目前約為 4.4,第三季末為 3.4。

  • Focusing on our outlook, we would like to give an estimate of what we see for the year 2003. With regard to quarterly estimates, we are sensitive to the fact that the timing of one or more system sales can significantly impact our results. Therefore, we have decided to de-emphasize the focus on quarterly estimates for revenues and unit shipments and give you our view of what we see for the coming year. Obviously we will update our annual projection as the year unfolds.

    聚焦於展望,我們想提供對 2003 年全年的估計。就季度估計而言,我們也注意到一筆或多筆系統銷售的時點可能會對我們的結果造成顯著影響。因此,我們決定降低對季度營收與出貨台數預估的著墨,並向各位提供我們對來年整體的看法。當然,隨著年度進展,我們會更新全年預測。

  • With that in mind, we have a positive outlook for continued revenue growth in 2003. We would like to reiterate that we expect full year to total between 85 and $100 million, representing approximately a 20-40% growth over 2002. We continue to see system usage increasing which drives higher recurring revenues. As a result, we expect recurring revenues to grow in excess of 50% over 2002. We anticipate full-year 2003 growth margin to be in the mid-50s. The first quarter of 2003 will likely dip down from the 55% recorded in Q4, and then rise again throughout year. We are holing the line on operating expenses and expect only modest increases over 2002. We expect operating expenses in the first quarter of 2003 to be down slightly from the fourth quarter of 2002. With our current sales outlook and continued improvements in margins and cost controls, we expect to achieve profitability by the fourth quarter of this year. We expect the average number of shares outstanding for EPS calculations to grow to 36.8 in Q1 2003 and average 37 million shares outstanding for the year.

    基於上述,我們對 2003 年營收持續成長抱持正向展望。我們再次重申,預期全年營收介於 8,500 萬至 1 億美元之間,約較 2002 年成長 20% 至 40%。我們持續看到系統使用量增加,進而帶動更高的經常性收入。因此,我們預期經常性收入將較 2002 年成長超過 50%。我們預期 2003 年全年毛利率將落在 50% 中段。2003 年第一季毛利率可能會較第四季的 55% 下滑,之後在全年逐步回升。我們將嚴控營運費用,預期僅較 2002 年小幅增加。我們預期 2003 年第一季營運費用將較 2002 年第四季略為下降。在目前的銷售展望以及毛利改善與成本控管持續進步下,我們預期可於今年第四季達成獲利。我們預期用於 EPS 計算的平均流通在外股數在 2003 年第一季將增至 3,680 萬股,全年平均約為 3,700 萬股。

  • With that I would like to turn it over to Aleks who will provide a summary of our latest sales and marketing highlights.

    接下來我想把時間交給 Aleks,由他為各位總結我們最新的銷售與行銷重點。

  • - Vice President, Business Development and Strategic Planning

    - Vice President, Business Development and Strategic Planning

  • Thank you, Susan. As was previously mentioned, we shipped 17 da Vinci surgical systems during the fourth quarter. We shipped 12 systems to U.S. hospitals, 1 to Europe and four to the rest of the world. Of the shipments made to the rest of the world, one went to Japan and the other three represented initial shipments into new international markets. After 12 months of planning, training and preparation with our new distributor partnering, we shipped the first da Vinci systems into Canada, Singapore and India.

    謝謝你,Susan。如先前所提,我們在第四季出貨了 17 套 da Vinci 手術系統。其中 12 套出貨至美國醫院、1 套至歐洲、4 套至世界其他地區。在出貨至世界其他地區的部分,其中 1 套至日本,另外 3 套則是首次出貨至新的國際市場。在與新的經銷合作夥伴經過 12 個月的規劃、訓練與準備後,我們首次將 da Vinci 系統出貨至加拿大、新加坡與印度。

  • We are delighted with our new distributors and look forward to developing these new markets for Intuitive. Of note is the sale to Escorts Heart Institute. India's premiere cardiac center. Escorts performed over 4,000 cardiac surgeries annually and is off to a quick and successful start with its da Vinci system. The sale to Escorts occurred prior to the 2002 winter International Society For Minimally Invasive Surgeons' conference, ISMICS, held in New Deli. This conference is widely attended by European as well as Asian cardiac surgeons. Dr. NareshTrehan of Escorts Heart Institute used the conference as a forum to promote several robotic surgeries which were broadcast live into the general session at ISMICS . Included in these broadcasts were several successful beating hearts, close chested [INAUDIBLE] procedures very well received by the audience. This type of customer commitment assures us that we picked the right clinical partner to open up the new market.

    我們對新的經銷商感到非常滿意,並期待為 Intuitive 開發這些新市場。值得一提的是對 Escorts Heart Institute 的銷售。該院是印度首屈一指的心臟中心。Escorts 每年進行超過 4,000 例心臟手術,並已迅速且成功地開始使用其 da Vinci 系統。對 Escorts 的銷售發生在 2002 年冬季微創外科醫師國際學會(International Society For Minimally Invasive Surgeons)年會 ISMICS 之前,該會議於新德里舉行。此會議有眾多歐洲及亞洲心臟外科醫師參與。Escorts Heart Institute 的 NareshTrehan 醫師利用該會議作為平台,推廣多項機器人手術,並在 ISMICS 的大會場次進行現場直播。直播內容包含多例成功的跳動心臟、閉胸式 [INAUDIBLE] 手術,獲得與會者高度好評。這類客戶投入讓我們確信,我們選對了臨床合作夥伴來開拓新市場。

  • To date, Intuitive penetrated the most prestigious hospitals in the world and this quarter was no different. On the academic side we shipped a Q4 system into the University of Chicago, Boston Children's Hospital and our first Canadian sale to Sacre Coure Hospital in Montreal. Also during the quarter, we made two additional sales of second da Vinci systems into existing accounts. We sold a second into Enrico [ph] Doctor's Hospital in Richmond, Virginia and Boston Children's Hospital as previously mentioned. That now makes a total of 11 sites with two da Vinci surgical systems. The second system at Boston Children's is significant in that it confirms this most important pediatric hospital's commitment to Intuitive Surgical. Boston Children's has also established a pediatric robotic training center at the facility.

    截至目前,Intuitive 已打入全球最具聲望的醫院,而本季也不例外。在學術端,我們於第四季出貨系統至芝加哥大學、波士頓兒童醫院,並完成我們在加拿大的首筆銷售:蒙特婁的 Sacre Coure 醫院。此外,本季我們也在既有客戶中新增兩筆第二套 da Vinci 系統的銷售。我們在維吉尼亞州里奇蒙的 Enrico [ph] Doctor's Hospital 售出第二套,並如前所述在波士頓兒童醫院也售出第二套。目前共有 11 個據點擁有兩套 da Vinci 手術系統。波士頓兒童醫院的第二套系統意義重大,因為這證實了這家最重要的兒科醫院對 Intuitive Surgical 的承諾。波士頓兒童醫院也已在院內設立兒科機器人訓練中心。

  • As has been the recent trend, we sold a large number of our fourth quarter systems into community hospitals. This quarter, 12 of the 17 systems shipped went to community hospitals. This continued high concentration into the segment confirms, as Lonnie described earlier, the real economic value that da Vinci provides to surgeons and hospitals.

    如同近期的趨勢,我們在第四季將大量系統售入社區醫院。本季出貨的 17 套系統中,有 12 套銷往社區醫院。如 Lonnie 先前所述,這種持續高度集中於該細分市場的情況,證實了達文西(da Vinci)為外科醫師與醫院帶來的真實經濟價值。

  • We have also seen a noticeable shift in the type of surgical procedures performed over the past few quarters. We now see a larger percentage of more complex higher value-add procedures in relation to simpler procedures. For example in general surgery, we now see a shift towards colon and rectal procedure as well as gastric procedures. In urology procedures such as prostatectomy are comprising a larger percentage of total procedures performed. And overall we are seeing more cardiac procedures which by their nature are more delicate and complex. We believe this is all very healthy. Showing that our customers are fulfilling the promise of the technology and seeing the value in working up the learning curve.

    過去幾個季度,我們也看到手術類型出現明顯轉變。相較於較簡單的手術,我們現在看到更高比例的、較複雜且附加價值更高的手術。例如在一般外科方面,我們看到趨勢轉向結腸與直腸手術,以及胃部手術。在泌尿科方面,例如前列腺切除術正占總手術量中更高的比例。整體而言,我們也看到更多心臟手術,而這類手術本質上更精細且更複雜。我們認為這一切都非常健康。這顯示我們的客戶正在實現這項技術的承諾,並在學習曲線上持續精進的過程中看見其價值。

  • With that I will turn the time over to David Shaw.

    接下來我把時間交給 David Shaw。

  • - Vice President, Legal Affairs and Corporate Counsel

    - Vice President, Legal Affairs and Corporate Counsel

  • Thanks, Aleks. This past quarter we continued to invest in our joint Delaware litigation with IBM against Computer Motion on our patent covering voice control surgical robots. As our December press release announced the Delaware court rejected Computer Motion's final prosecution latches [ph] defense and so entered judgment in our favor on the jury's verdict of $4.4 million. Computer Motion has since filed three post trial motions asking the court to throw out the jury's damage award on a variety of grounds arguing the verdict was not supported by sufficient evidence and was legally flawed. We believe the jury's verdict was proper and was adequately supported with evidence. We anticipate the court's decisions may issue shortly.

    謝謝你,Aleks。本季我們持續投入與 IBM 共同在德拉瓦州對 Computer Motion 提起的訴訟,該案涉及我們涵蓋語音控制手術機器人的專利。如我們 12 月的新聞稿所宣布,德拉瓦州法院駁回了 Computer Motion 最後的 prosecution latches [ph] 抗辯,因此依陪審團裁決判定我們勝訴,賠償金額為 440 萬美元。此後,Computer Motion 提出了三項審後動議,要求法院基於多項理由撤銷陪審團的損害賠償裁定,主張該裁決缺乏充分證據支持且在法律上有瑕疵。我們認為陪審團的裁決是適當的,且有充分證據支持。我們預期法院的裁定可能很快就會出爐。

  • As we said we would, we have now requested the Delaware court enter a permanent injunction barring future sales of Computer Motion's voice controlled Aesop [ph] induced products. Computer Motion has hired new legal council and has opposed our request for an injunction. Briefing is concluded and the court's decision may issue shortly.

    正如我們所說的,我們現已請求德拉瓦州法院核發永久禁制令,禁止未來銷售 Computer Motion 具語音控制的 Aesop [ph] induced 產品。Computer Motion 已聘請新的法律顧問,並反對我們的禁制令請求。書狀陳述已結束,法院的裁定可能很快就會出爐。

  • Turning now to our ongoing litigation against Computer Motion in California. First, Computer Motion has now asked to dismiss two of its own patents from suit. The two that we successfully invalidated in the recent patent [INAUDIBLE] interferences. We agreed to that request; thus we anticipate the 583 and 193 patents will soon no longer be part of the suit.

    接著談我們在加州對 Computer Motion 的持續訴訟。首先,Computer Motion 現已要求將其自身的兩件專利自本案中撤回。也就是我們在近期專利 [INAUDIBLE] 干涉程序中成功使其無效的那兩件。我們同意該請求;因此我們預期 583 與 193 號專利很快將不再是本案的一部分。

  • Second, last summer we filed four motions for summary judgment of noninfringement against four others of Computer Motion's patents. The court has now started to decide those motions. In November it decided the first in our favor, concluding [INAUDIBLE] how the da Vinci system uses the two master handles to control robotic arm movement does not infringe Computer Motion's 850 patent. That patent therefore also is no longer part of the suit. Of course Computer Motion can try to seek review of that motion at some point.

    第二,去年夏天我們就 Computer Motion 另外四件專利提出四項不侵權的簡易判決動議。法院現已開始對這些動議作出裁定。在 11 月,法院就第一項動議判我們勝訴,認定 [INAUDIBLE] 達文西系統如何使用兩個主控手柄來控制機械手臂運動,並未侵害 Computer Motion 的 850 號專利。因此該專利也不再是本案的一部分。當然,Computer Motion 仍可在某個時間點嘗試就該裁定尋求覆核。

  • We expect the court to decide our other three motions for summary judgment very soon. Once it does, the court indicated it would like to hold a status conference to discuss what remains of the case. At that status conference, we will ask for permission to file further summary judgment motions to address Computer Motion's other four patents, none of which we had the chance to address by motion. We believe the court at that conference will also consider how to manage the case schedule from here on out, including the trial date to accommodate everything that remains to be done in the case.

    我們預期法院將很快裁定我們其餘三項簡易判決動議。一旦裁定完成,法院表示希望召開一次狀態會議,討論案件剩餘部分。在該狀態會議上,我們將請求許可提出進一步的簡易判決動議,以處理 Computer Motion 其餘四件專利;對於這四件專利,我們先前尚無機會透過動議加以處理。我們相信法院也會在該會議上考量如何自此管理案件時程,包括為配合案件中仍需完成的事項而調整審判日期。

  • That completes what I have to say for today and I will pass the floor back to Lonnie.

    以上就是我今天要說的內容,接下來我把發言權交回給 Lonnie。

  • - President and CEO

    - President and CEO

  • That concludes the presentation and we will open floor to questions.

    簡報到此結束,我們將開放提問。

  • Operator

    Operator

  • Thank you. At this time we will have the question and answer session. If you have a question, we ask that you press star 1 on your telephone touch pad. If you need to cancel you may press star 2. That is star 1 if you have a question and star 2 to cancel. One moment while the questions register.

    謝謝。現在開始問答時間。若您有問題,請在電話按鍵上按星號 1。若要取消,請按星號 2。也就是:有問題請按星號 1,取消請按星號 2。請稍候,讓問題登記。

  • The first question comes from Rick Wise with Bear Stearns.

    第一個問題來自 Bear Stearns 的 Rick Wise。

  • How are you doing?

    你們好嗎?

  • - President and CEO

    - President and CEO

  • We are having a hard time hearing you.

    我們有點聽不清楚你說話。

  • First, you talked about the heart approval coming by the end of this year. I assume that's a very major event for you. I guess a couple of things. One, I would like you to reflect on what it could mean for '04. Are we likely to see some major potential acceleration from that? Second, a broader question. Has the FDA clarified what you need for the general cardiac approval? If I remember correctly, there were three approvals they wanted you to get before they gave that and where does that all stand?

    首先,你提到心臟適應症的核准會在今年年底前到來。我想那對你們而言是非常重大的事件。我有幾點想問。第一,我希望你談談這對 2004 年可能意味著什麼。我們是否可能因此看到一些顯著的加速成長潛力?第二個是更廣泛的問題:FDA 是否已釐清你們取得一般心臟適應症核准所需要的條件?如果我沒記錯,他們在給予該核准前希望你們先取得三項核准;目前進度如何?

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • Rick, it's Susan. There two elements there. In terms of how this plays into 2004, I think Aleks earlier mentioned that we are seeing momentum in the heart cases with the two clearances we have so far. We will obviously take people through a training pathway and a process to get up to doing a totally endoscopic stopped heart bypass [INAUDIBLe] to approve. There is a training pathway we can't under estimate the profits there. So, again, we see incremental increases, not a giant up surge. The FDA had conversations very early on with us on three types of cardiac procedures for cardiac clearance. That will be a dialogue we have once they had a chance to review the 5 and 10-K.

    Rick,我是 Susan。這裡有兩個面向。就這對 2004 年的影響而言,我想 Aleks 先前提到,我們在心臟手術案例方面,隨著目前已取得的兩項許可,正看到動能。我們顯然會帶領大家走過訓練路徑與流程,逐步提升到能執行完全內視鏡的停跳心冠狀動脈繞道手術 [INAUDIBLe] 以取得核准。這裡有一條訓練路徑,我們不能低估其中的獲利。因此,我們看到的是逐步增加,而不是巨大的暴增。FDA 很早就與我們就心臟適應症許可所涵蓋的三種類型心臟手術進行過討論。待他們有機會審閱 5 與 10-K 之後,我們將再就此展開對話。

  • - President and CEO

    - President and CEO

  • That was more of an informal guidance. Time will tell how to that proceeds.

    那比較像是非正式的指引。後續如何發展,時間會給出答案。

  • On the question about the sales range and the notion of being profitable by the fourth quarter, does the notion of profitability, are you there if you are at $85 million for the year or do you need to be at 90 or $100 million to get to the fourth quarter goal? Can you give us perspective on that, Lonnie?

    關於銷售區間以及第四季達成獲利的想法,所謂「獲利」的概念是:如果全年是 8,500 萬美元你們就能達成,還是需要到 9,000 萬或 1 億美元才能達到第四季目標?Lonnie,你能就此提供一些觀點嗎?

  • - President and CEO

    - President and CEO

  • I think that you know the goal is not to be profitable in any single quarter, but to be profitable and continue to be profitable. Clearly depending on how -- the fourth quarter at the end of each year is typically the strongest quarter. With $85 million, we may be profitable in the fourth quarter. But to be profitable on an ongoing basis, we will need to be in the higher end of that range.

    我想你知道,我們的目標不是在任何單一季度獲利,而是要獲利並且持續獲利。很明顯地,第四季通常是每年最強的一季。若全年達到 8,500 萬美元,我們可能在第四季獲利。但若要在持續基礎上獲利,我們需要落在該區間的較高端。

  • Okay and I want to make sure I understood. I think you preannounced $20 million for the fourth quarter. You came in at 21. Can you give more detail on what was there. Prices for [INAUDIBLE], did I understand correctly?

    好的,我想確認我理解正確。我記得你們先行預告第四季是 2,000 萬美元。實際結果是 2,100 萬。你能更詳細說明其中的因素嗎?是 [INAUDIBLE] 的價格嗎,我理解得對嗎?

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • No, it was a matter of when we have to estimate, there are always revenue recognition issues of the revenue. How much goes into deferred revenue and how much goes into current income. Those are issues we haven't had a chance to go through with auditor. That's why we erred on the side of conservative when we made that estimate.

    不,問題在於當我們必須進行估計時,收入的收入認列總是會有一些問題。有多少要列入遞延收入、有多少要列入當期收入。這些問題我們還沒有機會與審計師一起逐一檢視。因此在做那個估計時,我們採取了較為保守的作法。

  • Got it. Thanks.

    了解。謝謝。

  • Operator

    Operator

  • The next question comes from Charles Olsziewski with UBS Warburg.

    下一個問題來自 UBS Warburg 的 Charles Olsziewski。

  • No fair. He got it right. Two questions The as far as the lower warranty costs that boosted gross margins, Susan, what was the impact either in dollar terms of the boost to gross margin, and without that change, what would gross margins have been?

    這不公平。他答對了。兩個問題:關於較低的保固成本推升毛利率這件事,Susan,以金額來看對毛利率提升的影響是多少?如果沒有這個變動,毛利率會是多少?

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • This is Ben. I think that Susan mentioned also that there was a revenue of $400,000.

    我是 Ben。我想 Susan 也提到有 40 萬美元的收入。

  • Correct.

    沒錯。

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • So, the combination of that and the reduction of the warranty, if you compared a warranty reserve from the third quarter to the fourth quarter, you'll see that it decreased a bit. The impact of those two items probably impacted gross margin by two points.

    所以,把那項收入與保固費用的降低合併來看,如果你比較第三季到第四季的保固準備,你會看到它略有下降。這兩個項目的影響,可能讓毛利率提高了大約兩個百分點。

  • Staying with the revenue recognition of the $400,000, is that essentially procedures done during the quarter that you couldn't recognize as revenue?

    延續 40 萬美元的收入認列問題,那基本上是本季已完成的程序,但你們無法認列為收入嗎?

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • No..

    不是……

  • Disposals or reposeables, I should say, associated with those procedures until you got approval or what is the revenue recognition specifically?

    是與那些程序相關的耗材或可重複使用器械(我應該這麼說),直到你們取得核准才認列嗎?或是具體來說,收入認列的原因是什麼?

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • We were holding back some portion of a system revenue. A contention upon approval of the mitral valve cases even though we had actually collected the cash long ago. It was in accounting deferred revenue issue on a system.

    我們先暫緩認列某一套系統收入的一部分。那部分取決於二尖瓣病例的核准,儘管我們其實很久以前就已經收到了現金。那是某套系統在會計上屬於遞延收入的問題。

  • Okay. That's all I had. Thanks.

    好的。我就這些。謝謝。

  • Operator

    Operator

  • The next comes from Henry Binestein [ph] with Gagnon.

    下一位是來自 Gagnon 的 Henry Binestein [音]。

  • Hi, it's Neal Gagnon [ph] with Henry Binestein [ph] on the phone. Can you give us indication about your pipeline and backlog and also answer the question of when a machine system gets to the point were I think yours is, doctors and individual groups get together and start buying them because they can see a hard dollar return on their assets and makes money. What's going in that part?

    嗨,我是 Neal Gagnon [音],Henry Binestein [音] 也在線上。你們能否說明一下你們的銷售管線與訂單積壓(backlog),並回答這個問題:當一套機器系統發展到我認為你們目前這個階段時,醫師與個別團體會開始集結起來購買,因為他們看得到資產有明確的現金回報並能賺錢;這一塊目前的情況如何?

  • - President and CEO

    - President and CEO

  • Well, in terms of our visibility, I think it is not changed significantly from what it has been in the past and continues to be a fairly long purchase process. That can vary from institution to institution. In terms of groups buying, we have I think a couple of those. One, I think We have a couple others looking at it. These are trends that develop initially slowly. One or two. And people have a good experience and build confidence and others do the same. It's in the early stages at this point in time.

    嗯,就我們的能見度而言,我認為與過去相比並沒有顯著改變,採購流程仍然相當漫長。不同機構之間會有所差異。至於團體採購,我想我們已經有幾個案例。另外我想也有幾個正在評估。這些趨勢一開始通常發展得很慢。先是一、兩個。大家有了良好經驗、建立信心之後,其他人也會跟進。目前仍處於早期階段。

  • If I can throw in one more, please. What's been the trend in legal fees starting with the little of '02 and what you are thinking about going forward?

    如果可以的話我再加問一個。從 2002 年初開始,法律費用的趨勢如何?以及你們對未來的看法是什麼?

  • - Vice President, Legal Affairs and Corporate Counsel

    - Vice President, Legal Affairs and Corporate Counsel

  • I'll take a shot at it.

    我來試著回答。

  • In a nonnumerical way.

    用不提供數字的方式。

  • - Vice President, Legal Affairs and Corporate Counsel

    - Vice President, Legal Affairs and Corporate Counsel

  • I'll take a shot at that. We had a pretty high peak in the third quarter of 2002. That related to the trial that we had in Delaware. It dipped down from the third quarter to the fourth quarter. We don't disclose the absolute numbers, but we continue to spend money on the legal fronts of both the Delaware and California actions.

    我來試著回答。我們在 2002 年第三季有一個相當高的高峰。那與我們在德拉瓦州的審判有關。從第三季到第四季有下降。我們不揭露絕對金額,但我們仍持續在德拉瓦州與加州兩個訴訟案的法律戰線上投入費用。

  • Going forward we will stay at the fourth quarter levels or there abouts?

    往後看,我們會維持在第四季的水準或差不多的水準嗎?

  • - President and CEO

    - President and CEO

  • It really depends on what David said earlier which is when we have the conference and understand when the trial will be.

    這真的取決於 David 先前提到的,也就是我們何時召開會議並了解審判何時進行。

  • There is a significant investment and expert witness and still depositions and all the prep. Clearly the spending accelerates just prior and during trial.

    在專家證人方面有相當大的投入,還有證詞錄取(depositions)以及所有準備工作。很明顯地,支出會在審判前夕以及審判期間加速。

  • - President and CEO

    - President and CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Once again that is star 1 for additional questions. The next question comes from Rick Wise with Bear Stearns.

    再次提醒,如需追加提問請按星號 1。下一個問題來自 Bear Stearns 的 Rick Wise。

  • It's actually Sheila Mason [ph] here. For system placements, you guys had four in the rest of the world. Are you expecting a significant contribution from the rest of the world again in '03; and my second question is regarding instruments, accessories and services. What are expectations on percentage of sales for '03? I think it was 20% existing, or 20% for full year '02 and what your expectations are for 03. Thanks.

    其實是 Sheila Mason [音]。關於系統裝機(placements),你們在世界其他地區有四套。你們是否預期在 2003 年世界其他地區也會再次有顯著貢獻?第二個問題是關於器械、配件與服務。你們對 2003 年其占銷售額百分比的預期為何?我想 2002 全年大約是 20%(或現有為 20%),你們對 2003 年的預期是什麼?謝謝。

  • - Vice President, Business Development and Strategic Planning

    - Vice President, Business Development and Strategic Planning

  • I will take the first part of the question pertaining the to rest of the world. This is Aleks. If you go back 12 months and see when the cultivation period started for the sales that were recognized in the fourth quarter, you will see there is a pathway that we follow to make sure that we choose and qualify the right partners in the rest of the world market. We are well into that stage with several distributors in other parts of the world; however, I think it would be premature to tell you in Q1, you can expect a specific number and be truthful about the number. I will say that the momentum is growing in key international markets. The process of cultivating those distributors is picking up. I will say that it is going to continue to grow for us.

    我先回答與世界其他地區相關的第一部分。我是 Aleks。如果你回頭看 12 個月前、也就是第四季認列的銷售開始培育期(cultivation period)時,你會看到我們遵循的一套路徑,以確保在世界其他地區市場選擇並篩選合適的合作夥伴。我們已經與世界其他地區的數家經銷商深入進行到這個階段;不過,我認為在第一季就告訴你可以期待一個具體數字,並且對那個數字負責,還為時過早。我可以說的是,在關鍵的國際市場,動能正在增強。培育這些經銷商的流程正在加速。我會說這對我們而言將會持續成長。

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • For the second part of your question, we expect the recurring revenues to grow in excess of 50% year over year. We gave guidance on the total revenues of growing 20-40%. What is certainly going to happen is the percentage of revenues that are recurring is going to increase, but it tends to go up and down based off of the fluctuation that we have in the capital sales. I think you can probably get to the right answer if you model it.

    至於你問題的第二部分,我們預期經常性收入(recurring revenues)年增將超過 50%。我們對總收入的指引是成長 20% 到 40%。可以確定的是,收入中屬於經常性收入的占比會提高,但它會因資本設備銷售的波動而上下起伏。我想如果你用模型去推估,應該可以得到正確答案。

  • Okay. Thanks.

    好的。謝謝。

  • Operator

    Operator

  • The next question is from Dan Zenith [ph] with Chilton.

    下一個問題來自 Chilton 的 Dan Zenith [音]。

  • I wonder if you can give an update on new instrument introductions, including the fourth arm. And also can you discuss at all the progress being made with the treatment of atrial fibrillation and the devices on the market place in combination with the da Vinci surgical devices.

    我想請問你們能否更新一下新器械的推出進度,包括第四支手臂。另外,你們能否談談在心房顫動治療方面的進展,以及市面上的裝置如何與達文西手術系統搭配使用?

  • - Vice President, Business Development and Strategic Planning

    - Vice President, Business Development and Strategic Planning

  • Dan, it's Aleks. With regard to the fourth arm, we have done a great deal of testing with the fourth arm and shipped a number of units into our beta trials. We are looking and continuing to make progress with that as a commercial product. I don't know, to be honest, how that is reflected in the Q1 numbers, but we are continuing to make progress with forearm systems and the demand is definitely building for the fourth arm systems.

    Dan,我是 Aleks。關於第四支手臂,我們已對第四支手臂做了大量測試,並已將多套單元出貨到我們的 beta 試用中。我們正持續推進,將其作為商業化產品。老實說,我不確定這會如何反映在第一季的數字上,但我們持續在第四支手臂系統上取得進展,而且對第四支手臂系統的需求確實正在累積。

  • As far as the story that's unfolding in the industry with atrial fib, there are a number of companies are focused on different ablation catheters for the treatment of that disease. We are working closely with several of those companies. At the recent STS meeting, there was a great deal of interest in a minimally invasive approach to atrial fibrillation. I know that one of the accounts in New York, actually two of them, have reported they have done a minimally invasive procedure where they incorporate da Vinci as a delivery system for the specific catheters. So I will say the momentum and the appetite in that particular area is continuing to grow rapidly.

    就目前在心房顫動(atrial fib)這個領域的產業發展而言,有多家公司正專注於不同的消融導管,用於治療該疾病。我們正與其中幾家公司密切合作。在最近的 STS 會議上,對於以微創方式治療心房顫動有相當高的興趣。我知道紐約有一個客戶(其實是兩個)回報,他們已進行一種微創手術,並將達文西(da Vinci)作為特定導管的輸送系統。因此我會說,在那個特定領域的動能與需求仍在快速成長。

  • - President and CEO

    - President and CEO

  • On the other question, you raised an issue of where we stood on new instruments and that sort of thing. Obviously instrument development continues. We do have a new generation of five millimeter instruments that has a, I think we've shared before, that has a very new and effective risk. We are still refining that. We had a bunch of surgeons in last month, I guess. They used it in the lab on cadavers and it performed very, very well. So we are making good progress on that and that will be released sometime in the -- those instruments in the second quarter.

    至於另一個問題,你提到我們在新器械等方面的進展。顯然器械開發仍在持續。我們確實有新一代的 5 毫米器械,我想我們之前也分享過,它具備一個非常新且有效的風險(risk)。我們仍在進一步精進它。上個月我們邀請了一批外科醫師來訪。他們在實驗室以屍體進行操作測試,表現非常、非常好。因此我們在這方面進展良好,這些器械將在第二季的某個時間推出。

  • Thank you.

    謝謝。

  • Operator

    Operator

  • The next question is from Robert Natalie with Bear Stearns.

    下一個問題來自 Bear Stearns 的 Robert Natalie。

  • It's John Massie [ph]. Two quick questions for you. In terms of community hospital, can you give me the count for the U.S.? You said, I think 12 of 17. 12 shipments to the U.S.

    我是 John Massie [ph]。有兩個簡短問題。就社區醫院而言,你能提供美國的數量嗎?你說我想是 17 台中的 12 台。12 台出貨到美國。

  • - Vice President, Business Development and Strategic Planning

    - Vice President, Business Development and Strategic Planning

  • Yeah, 10 of those were into community hospitals. There were two academic centers recognized and that Boston Children's Hospital and the University of Chicago. Other than that, the remaining were nonacademic.

    對,其中有 10 台是出貨到社區醫院。有兩家是公認的學術中心,分別是波士頓兒童醫院(Boston Children's Hospital)以及芝加哥大學(University of Chicago)。除此之外,其餘都是非學術機構。

  • The second question is, you mentioned in a conference call about a month ago that there were two systems that slipped. That was part of the short or low end of the range. Can you tell me the progress on those two?

    第二個問題是,你在大約一個月前的電話會議中提到有兩套系統延後了。那是造成區間偏低或落在區間低端的一部分原因。你能談談那兩套的進度嗎?

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • This is Ben. No surprises there. At the end of the quarter, things don't stop. We just continue on and go ahead and do installations as a matter of course.

    我是 Ben。沒有任何意外。到了季度末,事情不會停止。我們只是照常持續推進,並按既定流程進行安裝。

  • So can I understand you are still working on them and haven't sealed the deal?

    所以我可以理解為你們仍在處理中,尚未敲定成交嗎?

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • We will give you a full report on the installations at the next conference call.

    我們會在下一次電話會議上,提供關於安裝情況的完整報告。

  • One other thing to clarify, a comment earlier on -- I think the true gross margin is about 53%, then if we strip out the warranty reserve and milestone payment?

    另外想釐清一點,你先前提到——我想真正的毛利率大約是 53%,如果我們把保固準備金和里程碑付款剔除的話?

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • That's correct.

    沒錯。

  • Operator

    Operator

  • At this time we have time for more question. I do show the next question comes from Charles Olsziewski.

    目前我們還有時間再回答更多問題。我看到下一個問題來自 Charles Olsziewski。

  • I will try to make this quick. I got three little ones. If the gross margins are going to dip sequentially in the first quarter, and given your guidance, would it be fair to assume they will end somewhere in the high 50s, Ben.

    我會盡量快一點。我家裡有三個小孩。如果第一季毛利率會較前一季下滑,並且依照你們的指引,是否可以合理假設到年底時會落在接近 50% 後段(high 50s),Ben?

  • - Vice President, Finance, CFO and Assistant Secretary

    - Vice President, Finance, CFO and Assistant Secretary

  • We said the mid-50s.

    我們說的是 50% 中段(mid-50s)。

  • No, I meant leaving the year, in other words the fourth quarter, is that fair?

    不,我的意思是年底,也就是第四季結束時,這樣的假設合理嗎?

  • - Vice President, Treasurer and Corporate Controller

    - Vice President, Treasurer and Corporate Controller

  • Yeah, we think it will average the mid-50s for the year.

    對,我們認為全年平均會在 50% 中段(mid-50s)。

  • Okay. I will ask one more. As far as -- Computer Motion showed a pretty sharp growth sequentially in their most recent quarter which they are yet to release the full results, but clearly just the top line they released, are you seeing them head to head or are they selling into different places than you are? How would you characterize what's going on from a competitive standpoint?

    好的。我再問一個。關於——Computer Motion 在最近一季的季對季成長看起來相當明顯,他們尚未公布完整結果,但從他們已公布的營收(top line)來看很清楚。你們是否在市場上與他們正面交鋒,還是他們銷售到的地方與你們不同?從競爭角度來看,你會如何描述目前的情況?

  • - President and CEO

    - President and CEO

  • I think -- I guess my comment is I think the numbers they released if you looked at the fourth quarter in the last two years to be pretty flat. We are seeing them. They've increased their sales organization and they are clearly very active in the market.

    我想——我的看法是,如果你看他們過去兩年的第四季,所公布的數字其實相當持平。我們確實有看到他們。他們擴增了銷售組織,而且顯然在市場上非常積極。

  • Thanks.

    謝謝。

  • - President and CEO

    - President and CEO

  • That's our last question. Let me close with summarizing the highlights of the fourth quarter.

    這是我們最後一個問題。我最後用第四季重點摘要作結。

  • Again we achieved record revenue of $21.1 million. We shipped 17 da Vinci systems. Ending the year with 149 da Vinci installations. We grew recurring revenue to $4.7 million, up 105% from prior year. We improved gross margin to 55% or a net 53% after the unusual adjustments. We had a cash positive quarter ending with $50.8 million in cash. We shipped initial systems into three new international markets. Canada, India and Singapore. We obtained the first cardiac clearance for mitral valve repair and subsequently added a second with atrial septal defect closure. And we continue to build our install base and its associated recurring revenue stream.

    我們再次達成創紀錄的營收 2,110 萬美元。我們出貨 17 套達文西(da Vinci)系統。年底達文西安裝量累計為 149 套。我們將經常性收入提升至 470 萬美元,較去年同期成長 105%。我們將毛利率提升至 55%,若扣除一次性調整後,淨毛利率為 53%。我們該季現金流為正,期末現金為 5,080 萬美元。我們在三個新的國際市場出貨首批系統。加拿大、印度與新加坡。我們取得首個心臟適應症核准,用於二尖瓣修補,之後又新增第二項核准:心房中隔缺損封堵。我們持續擴大安裝基礎及其所帶來的經常性收入來源。

  • That concludes today's call. We thank you for participation and look forward to talking to you in about three months.

    今天的電話會議到此結束。感謝各位參與,並期待大約三個月後再與各位交流。

  • Operator

    Operator

  • Once again we would like to thank everyone for attending the ISRG teleconference and have a pleasant day.

    再次感謝各位參加 ISRG 電話會議,祝各位有美好的一天。